Page 23 - உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் மாதிரி பட்டியல்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

F Hoffmann-La Roche Ltd: FDA approves Roche s OCREVUS (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis

(2) Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen Shorter infusion time will further improve the twice-yearly treatment experience for OCREVUS, the only B-cell therapy for relapsing and primary progressive MS with a twice-yearly dosing schedule Basel, 14 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The approval was based on data from the randomised, double-blind ENSEMBLE PLUS study.

United statesNathalie meetzJon kaspar bayardLevi garrawayDaniel grotzkyKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLoren kalmLisa tuomiPatrick barthKarsten kleineDrug administrationHead of global product development

F Hoffmann-La Roche Ltd: Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

F Hoffmann-La Roche Ltd: Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNathalie meetzDaniel grotzkyJon kaspar bayardKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLisa tuomiActemra roactemraThomas schineckerLoren kalmPatrick barthKarsten kleineDrug administration

Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infectionRoche will be able to ramp up to a double-digit million number of tests per

United statesNathalie meetzDaniel grotzkyActemra roactemraThomas schineckerPatrick barthKarsten kleineDrug administrationRoche groupPharmaceuticals industryEuropean centre for disease preventionRoche group media relationsSevere acute respiratory syndrome coronavirusEmergency use authorisationUse authorisationWorld health organization model lists

F Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

F. Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 25.8 DFS, HR (95% CI) (0.19-0.60) About bladder cancer and muscle-invasive urothelial cancer In 2018, there were over half a million new cases of bladder cancer diagnosed globally, with approximately 200,000 deaths from the disease. 4 Urothelial cancer is the most common type of bladder cancer, accounting for about 90-95% of all cases. 5 MIUC is a type of urothelial cancer that has spread into the muscle of the bladder, ureter or renal pelvis. 6 Approximately 25% of new cases of bladder cancer are diagnosed with muscle-invasive disease,

United statesNathalie meetzLevi garrawayDaniel grotzkyJon kaspar bayardKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLisa tuomiLoren kalmPatrick barthKarsten kleineAmerican society of clinical oncologyUrology care foundation

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

F. Hoffmann-La Roche Ltd Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNA The goal of current treatment in people with MIUC is to provide early intervention to reduce the risk of the disease recurring or spreading to other parts of the body

United statesNathalie meetzLevi garrawayDaniel grotzkyPatrick barthKarsten kleineAmerican society of clinical oncologyUrology care foundationOncology esmo io virtual congressNational collaborating centre for cancerHead of global product developmentOncology virtual congressNational institute for healthEuropean society for medical oncology immunoEsmo io virtual congressRoche group